Trial reportModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2008
Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer.
Trial report in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 59 citations in OpenAlex.
- Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning.Respiratory research · 2023Trial
- An early lung cancer diagnosis model for non-smokers incorporating ct imaging analysis and circulating genetically abnormal cells (CACs).BMC cancer · 2025Article
- Review
- Diagnostic value of circulating genetically abnormal cells to support computed tomography for benign and malignant pulmonary nodules.BMC cancer · 2022Article
- The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling.Annals of translational medicine · 2022Article
- Sputum analysis by flow cytometry; an effective platform to analyze the lung environment.PloS one · 2022Article
- High-Throughput Detection of Multiple miRNAs and Methylated DNA by Droplet Digital PCR.Journal of personalized medicine · 2021Article
- Microbiota Biomarkers for Lung Cancer.Diagnostics (Basel, Switzerland) · 2021Article
- Sputum long non-coding RNA biomarkers for diagnosis of lung cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- Integrating Circulating Immunological and Sputum Biomarkers for the Early Detection of Lung Cancer.Biomarkers in cancer · 2018Article
- Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Article
- A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinoma.Oncotarget · 2017Article
- Article
- Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection.Clinical epigenetics · 2016Article
- Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- Analysis of Lung Flute-collected Sputum for Lung Cancer Diagnosis.Biomarker insights · 2015Article
- Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Article
- Molecular sputum analysis for the diagnosis of lung cancer.British journal of cancer · 2013Review
- The state of molecular biomarkers for the early detection of lung cancer.Cancer prevention research (Philadelphia, Pa.) · 2012Review
- Sputum-based molecular biomarkers for the early detection of lung cancer: limitations and promise.Cancers · 2011Article
Corrections and comments
- Erratum issuedJiang, Xiaoying Gao Feng [corrected to Gao, Xiaoying]; Jiang, Feng [added]
- Erratum issued
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
Detection of lung cancer by sputum cytology has low sensitivity but is noninvasive and, if improved, could be a powerful tool for early lung cancer detection. To evaluate whether the accuracy of diagnosing lung cancer by evaluating sputa for cytologic atypia and genetic abnormalities is greater than that of conventional cytology alone, automated scoring of genetic abnormalities for 3p22.1 and 10q22.3 (SP-A) by fluorescence in situ hybridization (FISH) and conventional cytology was done on sputa from 35 subjects with lung cancer, 25 high-risk smokers, and 6 healthy control subjects. Multivariate analysis was performed to select variables that most accurately predicted lung cancer. A model of probability for the presence of lung cancer was derived for each subject. Cells exfoliated from patients with lung cancer contained genetic aberrations and cytologic atypias at significantly higher levels than in those from control subjects. When combined with cytologic atypia, a model of risk for lung cancer was derived that had 74% sensitivity and 82% specificity to predict the presence of lung cancer, whereas conventional cytology achieved only 37% sensitivity and 87% specificity. For diagnosing lung cancer in sputum, a combination of molecular and cytologic variables was superior to using conventional cytology alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.